Dai Ogata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Dai Ogata has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
- Kenjiro Namikawa
Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
60 shared publications - Naoya Yamazaki
Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
55 shared publications - Eiji Nakano
Department of Dermatologic Oncology National Cancer Center Hospital Tokyo Japan
43 shared publications - Akira Takahashi
National Cancer Center Hospital East 3 Department of Dermatologic Oncology Kashiwa, Japan
21 shared publications - Shusuke Yoshikawa
Department of Dermatology Shizuoka Cancer Center Shizuoka Japan
18 shared publications Akira Takahashi
Dermatology, National Cancer Center-Hospital East, Kashiwa, Chiba Prefecture, Japan
17 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
Association of pretreatment immune microenvironment profile with boron neutron capture therapy efficacy in cutaneous tumors: results from an ancillary multiplex immunofluorescence study
Boron neutron capture therapy (BNCT), an emerging novel radiotherapy modality, has shown immunological relevance in preclinical models. Although the safety and efficacy of BNCT for cutaneous tumors have been evaluated in a Phase I clinical trial, studies using human clinical specimens remain limited. In this exploratory translational study, we aimed to investigate pretreatment immune microenvironmental features in patients treated with BNCT and to descriptively assess their relationship with clinical response. To this end, formalin-fixed paraffin-embedded pretreatment biopsy samples obtained from a Phase I clinical trial of BNCT for cutaneous tumors were analyzed in three responders and three non-responders. Multiplex immunofluorescent staining was performed using CD8+ T-cell and dendritic cell (DC) antibody panels to assess the phenotypes and spatial relationships of immune cells within the tumor microenvironment. At baseline, responders tended to show higher densities of total T cells, CD8+ T cells, DCs and mature DC-like cells than non-responders. CD8+ T cells in responders tended to include higher proportions of granzyme B+ and programmed cell death protein 1-positive cells, and spatial analysis showed closer proximity between CD8+ T cells and mature DC-like cells. In contrast, the proportions of programmed death-ligand 1-positive cells among DCs and tumor cells were higher in non-responders than in responders. These descriptive findings suggest that pretreatment immune microenvironmental features may warrant further investigation as potential factors related to clinical response to BNCT.
- 27 October 2026
- Published by Oxford University Press (OUP) in Journal of Radiation Research
Open AccessAssociation of pretreatment immune microenvironment profile with boron neutron capture therapy efficacy in cutaneous tumors: results from an ancillary multiplex immunofluorescence study
Boron neutron capture therapy (BNCT), an emerging novel radiotherapy modality, has shown immunological relevance in preclinical models. Although the safety and efficacy of BNCT for cutaneous tumors have been evaluated in a Phase I clinical trial, studies using human clinical specimens remain limited. In this exploratory translational study, we aimed to investigate pretreatment immune microenvironmental features in patients treated with BNCT and to descriptively assess their relationship with clinical response. To this end, formalin-fixed paraffin-embedded pretreatment biopsy samples obtained from a Phase I clinical trial of BNCT for cutaneous tumors were analyzed in three responders and three non-responders. Multiplex immunofluorescent staining was performed using CD8+ T-cell and dendritic cell (DC) antibody panels to assess the phenotypes and spatial relationships of immune cells within the tumor microenvironment. At baseline, responders tended to show higher densities of total T cells, CD8+ T cells, DCs and mature DC-like cells than non-responders. CD8+ T cells in responders tended to include higher proportions of granzyme B+ and programmed cell death protein 1-positive cells, and spatial analysis showed closer proximity between CD8+ T cells and mature DC-like cells. In contrast, the proportions of programmed death-ligand 1-positive cells among DCs and tumor cells were higher in non-responders than in responders. These descriptive findings suggest that pretreatment immune microenvironmental features may warrant further investigation as potential factors related to clinical response to BNCT.
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Extramammary Paget disease with bilateral sentinel lymph node biopsy: a multicentre study of lymphatic patterns and outcomes
Background: Extramammary Paget disease (EMPD) can metastasize to lymph nodes or distant sites. Sentinel lymph node biopsy (SLNB) is recommended for invasive EMPD without clinical nodal involvement. Objectives: Lesions near or across the midline may show bilateral lymphatic drainage, but the clinical significance of bilateral SLNB remains unclear. This study evaluated the metastatic distribution of sentinel lymph nodes (SLNs) and its association with clinicopathological features, lymphatic drainage patterns and survival in patients undergoing bilateral SLNB. Methods: We retrospectively reviewed 147 patients with EMPD who underwent bilateral SLNB at three institutions between 2015 and 2025. Tumour characteristics, SLN status, recurrence and survival outcomes were analysed. Patients were stratified as bilateral negative, unilateral positive or bilateral positive. Clinicopathological features, lymphatic drainage patterns and survival outcomes were compared, including overall survival, recurrence-free survival (RFS) and disease-free survival (DFS). Results: Bilateral SLN positivity was detected in eight male patients with genital nodular lesions. Unilateral positivity occurred in 12 patients, and 127 were bilaterally negative. Contralateral SLNs were frequently negative despite lesions crossing the midline, although bilateral metastases developed in two patients. Four ectopic lower-abdominal lesions were identified, two with irregular drainage. Patients with bilaterally negative SLNs had significantly better survival than those with SLN metastases. No significant differences in RFS or DFS were observed between the unilateral- and bilateral-positive groups. Conclusions: Bilateral SLN positivity is rare and limited to male genital cases. It was not associated with worse disease-related outcomes than unilateral positivity. Risk of bilateral metastasis appears to depend more on tumour location than intrinsic aggressiveness.
- 17 October 2026
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
Extramammary Paget disease with bilateral sentinel lymph node biopsy: a multicentre study of lymphatic patterns and outcomes
Background: Extramammary Paget disease (EMPD) can metastasize to lymph nodes or distant sites. Sentinel lymph node biopsy (SLNB) is recommended for invasive EMPD without clinical nodal involvement. Objectives: Lesions near or across the midline may show bilateral lymphatic drainage, but the clinical significance of bilateral SLNB remains unclear. This study evaluated the metastatic distribution of sentinel lymph nodes (SLNs) and its association with clinicopathological features, lymphatic drainage patterns and survival in patients undergoing bilateral SLNB. Methods: We retrospectively reviewed 147 patients with EMPD who underwent bilateral SLNB at three institutions between 2015 and 2025. Tumour characteristics, SLN status, recurrence and survival outcomes were analysed. Patients were stratified as bilateral negative, unilateral positive or bilateral positive. Clinicopathological features, lymphatic drainage patterns and survival outcomes were compared, including overall survival, recurrence-free survival (RFS) and disease-free survival (DFS). Results: Bilateral SLN positivity was detected in eight male patients with genital nodular lesions. Unilateral positivity occurred in 12 patients, and 127 were bilaterally negative. Contralateral SLNs were frequently negative despite lesions crossing the midline, although bilateral metastases developed in two patients. Four ectopic lower-abdominal lesions were identified, two with irregular drainage. Patients with bilaterally negative SLNs had significantly better survival than those with SLN metastases. No significant differences in RFS or DFS were observed between the unilateral- and bilateral-positive groups. Conclusions: Bilateral SLN positivity is rare and limited to male genital cases. It was not associated with worse disease-related outcomes than unilateral positivity. Risk of bilateral metastasis appears to depend more on tumour location than intrinsic aggressiveness.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Risk for recurrence based on ctDNA detection during surveillance. Overall observed rate of relapse at data cutoff (A and B) and Kaplan–Meier estimates of probability of recurrence over time (C and D) by anatomic site based on longitudinal ctDNA detection after surgery. A and C, Never detected; (B and D) ever detected. Three patients with detectable ctDNA before or during adjuvant therapy cleared ctDNA at later timepoints without recurrence.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Risk for recurrence based on ctDNA detection during surveillance. Overall observed rate of relapse at data cutoff (A and B) and Kaplan–Meier estimates of probability of recurrence over time (C and D) by anatomic site based on longitudinal ctDNA detection after surgery. A and C, Never detected; (B and D) ever detected. Three patients with detectable ctDNA before or during adjuvant therapy cleared ctDNA at later timepoints without recurrence.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Detectable ctDNA during surveillance is associated with higher risk for recurrence and death from melanoma. Kaplan–Meier estimates of probability of distant recurrence (A), any recurrence (B), or OS (C) based on whether ctDNA was ever or never detected during longitudinal surveillance after surgery. HRs and P values corresponding to the landmark survival analysis at 12, 18, and 24 months after surgery can be found in Supplementary Table S4.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Detectable ctDNA during surveillance is associated with higher risk for recurrence and death from melanoma. Kaplan–Meier estimates of probability of distant recurrence (A), any recurrence (B), or OS (C) based on whether ctDNA was ever or never detected during longitudinal surveillance after surgery. HRs and P values corresponding to the landmark survival analysis at 12, 18, and 24 months after surgery can be found in Supplementary Table S4.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival (OS) benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molecular residual disease (MRD) assays may influence management. We validated a tissue-free MRD assay in 48 patients with clinical stage II to III melanoma treated with surgery (52% nonacral cutaneous, 31% acral, and 17% mucosal). The assay detects MRD through bioinformatic analysis of methylation signals across >20,000 epigenomic regions. Plasma samples (n = 281; 280 successfully reported) were prospectively collected before surgery, at day 28, and every 3 to 6 months thereafter. Associations among MRD detection, recurrence, and OS were analyzed. At a median follow-up of 34.6 months with 27 recurrence events, postoperative surveillance sensitivity for distant recurrence was 81% with 100% posttreatment specificity. The median lead time between MRD detection and radiographic recurrence was 70.5 days. Surveillance MRD detection was associated with increased recurrence risk [hazard ratio (HR), 26.55; 95% confidence interval (CI), 2.86–246.58; P = 0.004]. Similarly, MRD detection 28 days postoperatively independently predicted recurrence (HR, 11.70; 95% CI, 3.09–43.76; P < 0.001) and death (HR, 31.14; 95% CI, 5.37–221.1; P < 0.001). Tissue-free epigenomic MRD detection was sensitive, specific, and significantly associated with recurrence and melanoma-related death. These findings support the use of this assay in melanoma as a rapid, noninvasive approach for earlier identification of patients at high risk for recurrence, enabling refined treatment and surveillance strategies. Significance:Prognostic tools for high-risk melanoma rely on baseline factors with limited dynamic risk assessment. A tissue-free MRD assay demonstrated high sensitivity and specificity for distant recurrence detection, identifying molecular relapse before radiographic recurrence. Postoperative MRD detection was strongly associated with recurrence and melanoma-related death, enabling refined treatment and surveillance strategies.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival (OS) benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molecular residual disease (MRD) assays may influence management. We validated a tissue-free MRD assay in 48 patients with clinical stage II to III melanoma treated with surgery (52% nonacral cutaneous, 31% acral, and 17% mucosal). The assay detects MRD through bioinformatic analysis of methylation signals across >20,000 epigenomic regions. Plasma samples (n = 281; 280 successfully reported) were prospectively collected before surgery, at day 28, and every 3 to 6 months thereafter. Associations among MRD detection, recurrence, and OS were analyzed. At a median follow-up of 34.6 months with 27 recurrence events, postoperative surveillance sensitivity for distant recurrence was 81% with 100% posttreatment specificity. The median lead time between MRD detection and radiographic recurrence was 70.5 days. Surveillance MRD detection was associated with increased recurrence risk [hazard ratio (HR), 26.55; 95% confidence interval (CI), 2.86–246.58; P = 0.004]. Similarly, MRD detection 28 days postoperatively independently predicted recurrence (HR, 11.70; 95% CI, 3.09–43.76; P < 0.001) and death (HR, 31.14; 95% CI, 5.37–221.1; P < 0.001). Tissue-free epigenomic MRD detection was sensitive, specific, and significantly associated with recurrence and melanoma-related death. These findings support the use of this assay in melanoma as a rapid, noninvasive approach for earlier identification of patients at high risk for recurrence, enabling refined treatment and surveillance strategies. Significance:Prognostic tools for high-risk melanoma rely on baseline factors with limited dynamic risk assessment. A tissue-free MRD assay demonstrated high sensitivity and specificity for distant recurrence detection, identifying molecular relapse before radiographic recurrence. Postoperative MRD detection was strongly associated with recurrence and melanoma-related death, enabling refined treatment and surveillance strategies.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
CtDNA detection increases with surveillance sampling and is associated with lead time prior to recurrence. A, Kaplan–Meier estimate of cumulative sensitivity of ctDNA detection with serial sampling in patients with recurrence. B, Timing of first ctDNA detection (day 28 postoperatively, after day 28 but prior to recurrence, or at recurrence) among 27 patients with recurrence based on anatomic location of recurrence. C, The median lead time among 18 samples with ctDNA detected in patients with recurrence was 70.5 days (IQR, 22.8–140.8 days) but ranged up to 273 days. D, Kaplan–Meier estimate of cumulative probability of ctDNA detection in all patients with stage II–III melanoma.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
CtDNA detection increases with surveillance sampling and is associated with lead time prior to recurrence. A, Kaplan–Meier estimate of cumulative sensitivity of ctDNA detection with serial sampling in patients with recurrence. B, Timing of first ctDNA detection (day 28 postoperatively, after day 28 but prior to recurrence, or at recurrence) among 27 patients with recurrence based on anatomic location of recurrence. C, The median lead time among 18 samples with ctDNA detected in patients with recurrence was 70.5 days (IQR, 22.8–140.8 days) but ranged up to 273 days. D, Kaplan–Meier estimate of cumulative probability of ctDNA detection in all patients with stage II–III melanoma.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Swimmer plots depicting ctDNA results for patients included in the surveillance analysis. A, Patients with recurrence; (B) patients with no recurrence at data cutoff. pTNM, pathologic tumor–node–metastasis.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Swimmer plots depicting ctDNA results for patients included in the surveillance analysis. A, Patients with recurrence; (B) patients with no recurrence at data cutoff. pTNM, pathologic tumor–node–metastasis.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Detectable ctDNA at day 28 after surgery is associated with higher risk for recurrence and death from melanoma. A, Cox proportional hazard analysis of clinical factors associated with recurrence (***, P < 0.0001; *, P < 0.05) and Kaplan–Meier estimates for (B) any recurrence, (C) distant recurrence, and (D) OS based on ctDNA detection 28 days after surgery. HRs and P values can be found in Supplementary Table S5.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Detectable ctDNA at day 28 after surgery is associated with higher risk for recurrence and death from melanoma. A, Cox proportional hazard analysis of clinical factors associated with recurrence (***, P < 0.0001; *, P < 0.05) and Kaplan–Meier estimates for (B) any recurrence, (C) distant recurrence, and (D) OS based on ctDNA detection 28 days after surgery. HRs and P values can be found in Supplementary Table S5.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Supplementary Figure 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Supplementary Table 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)
Supplementary Table 1 from Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)